Cargando…
Recent advances in the production of recombinant glycoconjugate vaccines
Glycoconjugate vaccines against bacteria are one of the success stories of modern medicine and have led to a significant reduction in the global occurrence of bacterial meningitis and pneumonia. Glycoconjugate vaccines are produced by covalently linking a bacterial polysaccharide (usually capsule, o...
Autores principales: | Kay, Emily, Cuccui, Jon, Wren, Brendan W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494827/ https://www.ncbi.nlm.nih.gov/pubmed/31069118 http://dx.doi.org/10.1038/s41541-019-0110-z |
Ejemplares similares
-
Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines
por: Passmore, Ian J., et al.
Publicado: (2019) -
Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines
por: Kay, Emily J., et al.
Publicado: (2022) -
Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis
por: Cuccui, Jon, et al.
Publicado: (2013) -
Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli
por: Samaras, Jasmin J., et al.
Publicado: (2021) -
Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine
por: Herbert, Jenny A., et al.
Publicado: (2018)